LAURUS LABS Ltd (LAURUSLABS) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-1.02%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 28.0%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 18.3%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹2,343.99

200-Day DMA ● Overlay

₹2,173.96

14-Day RSI ● Overlay

48.4 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹1.09 Lakh Cr

Large cap

Stock P/E (TTM) Valuation

99.7x

Price / EPS

Book Value (₹) Assets

₹98.2

P/B: 20.6x

ROE (%) Quality

18.3%

Net Profit / Equity

ROCE (%) Efficiency

17.8%

EBIT / Capital

Dividend Yield Yield

0.10%

Face Value: ₹10

Debt / Equity Solvency

0.48x

Manageable

EPS (TTM) Per Share

₹20.25

Trailing 12M

OPM (%) Spread

28.0%

EBITDA Margin

Free Cash Flow Cash

₹560.00 Cr

CFO - Capex

About LAURUS LABS Ltd

LAURUS LABS Ltd (LAURUSLABS) is an Indian publicly traded enterprise listed on the National Stock Exchange (NSE).

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 20.2% × Turnover: 0.85x × Leverage: 1.48x = ROE: 18.3%

✓ Company Strengths (Pros)

• Delivers solid shareholder returns with an ROE of 18.3%.
• Maintains healthy operating profit margins of ~28.0%.

⚠ Key Considerations & Risks (Cons)

• Stock is trading at a premium of 20.6x its book value.
• Commanding an elevated valuation multiple with P/E at 99.7x.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹7,270 Cr

Latest PAT

₹1,091 Cr

EPS (TTM)

₹20.25

OPM %

28.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹1,182 Cr	₹1,224 Cr	₹1,195 Cr	₹1,440 Cr	₹1,195 Cr	₹1,224 Cr	₹1,415 Cr	₹1,720 Cr	₹1,570 Cr	₹1,653 Cr	₹1,778 Cr	₹1,812 Cr	₹2,026 Cr
Operating Profit (EBITDA)	₹167.00 Cr	₹188.00 Cr	₹181.00 Cr	₹241.00 Cr	₹171.00 Cr	₹178.00 Cr	₹285.00 Cr	₹421.00 Cr	₹382.00 Cr	₹403.00 Cr	₹480.00 Cr	₹512.00 Cr	₹638.00 Cr
OPM %	14.0%	15.0%	15.0%	17.0%	14.0%	15.0%	20.0%	24.0%	24.0%	24.0%	27.0%	28.0%	32.0%
Interest Expense	₹39.00 Cr	₹42.00 Cr	₹51.00 Cr	₹50.00 Cr	₹49.00 Cr	₹53.00 Cr	₹58.00 Cr	₹56.00 Cr	₹52.00 Cr	₹40.00 Cr	₹39.00 Cr	₹40.00 Cr	₹42.00 Cr
Depreciation	₹91.00 Cr	₹93.00 Cr	₹98.00 Cr	₹102.00 Cr	₹106.00 Cr	₹108.00 Cr	₹106.00 Cr	₹110.00 Cr	₹117.00 Cr	₹120.00 Cr	₹121.00 Cr	₹122.00 Cr	₹124.00 Cr
Profit before Tax (PBT)	₹41.00 Cr	₹54.00 Cr	₹35.00 Cr	₹107.00 Cr	₹18.00 Cr	₹23.00 Cr	₹131.00 Cr	₹312.00 Cr	₹224.00 Cr	₹270.00 Cr	₹327.00 Cr	₹361.00 Cr	₹481.00 Cr
Net Profit (PAT)	₹27.00 Cr	₹37.00 Cr	₹23.00 Cr	₹75.00 Cr	₹13.00 Cr	₹20.00 Cr	₹93.00 Cr	₹233.00 Cr	₹162.00 Cr	₹194.00 Cr	₹252.00 Cr	₹282.00 Cr	₹362.00 Cr
EPS in ₹	₹0.46	₹0.69	₹0.43	₹1.40	₹0.23	₹0.37	₹1.71	₹4.33	₹3.02	₹3.61	₹4.66	₹5.17	₹6.80

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	₹1,327 Cr	₹1,778 Cr	₹1,905 Cr	₹2,056 Cr	₹2,292 Cr	₹2,832 Cr	₹4,814 Cr	₹4,936 Cr	₹6,041 Cr	₹5,041 Cr	₹5,554 Cr	₹6,813 Cr	₹7,270 Cr
Expenses	₹1,126 Cr	₹1,415 Cr	₹1,497 Cr	₹1,642 Cr	₹1,935 Cr	₹2,266 Cr	₹3,262 Cr	₹3,512 Cr	₹4,448 Cr	₹4,261 Cr	₹4,499 Cr	₹5,028 Cr	₹5,236 Cr
Operating Profit	₹200.00 Cr	₹362.00 Cr	₹408.00 Cr	₹414.00 Cr	₹357.00 Cr	₹565.00 Cr	₹1,552 Cr	₹1,424 Cr	₹1,592 Cr	₹779.00 Cr	₹1,055 Cr	₹1,785 Cr	₹2,034 Cr
OPM %	15%	20%	21%	20%	16%	20%	32%	29%	26%	15%	19%	26%	28%
Interest	₹106.00 Cr	₹111.00 Cr	₹100.00 Cr	₹80.00 Cr	₹88.00 Cr	₹90.00 Cr	₹68.00 Cr	₹102.00 Cr	₹165.00 Cr	₹183.00 Cr	₹216.00 Cr	₹171.00 Cr	₹161.00 Cr
Depreciation	₹62.00 Cr	₹86.00 Cr	₹106.00 Cr	₹125.00 Cr	₹164.00 Cr	₹187.00 Cr	₹205.00 Cr	₹251.00 Cr	₹324.00 Cr	₹385.00 Cr	₹430.00 Cr	₹480.00 Cr	₹487.00 Cr
Profit before Tax	₹67.00 Cr	₹169.00 Cr	₹234.00 Cr	₹237.00 Cr	₹120.00 Cr	₹294.00 Cr	₹1,301 Cr	₹1,084 Cr	₹1,109 Cr	₹236.00 Cr	₹484.00 Cr	₹1,182 Cr	₹1,439 Cr
Net Profit	₹68.00 Cr	₹134.00 Cr	₹190.00 Cr	₹168.00 Cr	₹94.00 Cr	₹255.00 Cr	₹984.00 Cr	₹832.00 Cr	₹793.00 Cr	₹162.00 Cr	₹358.00 Cr	₹890.00 Cr	₹1,091 Cr
EPS in Rs	8.81	16.97	3.60	3.16	1.76	4.77	18.33	15.40	14.67	2.98	6.64	16.46	20.24

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	₹16.00 Cr	₹16.00 Cr	₹106.00 Cr	₹106.00 Cr	₹106.00 Cr	₹107.00 Cr	₹107.00 Cr	₹107.00 Cr	₹108.00 Cr	₹108.00 Cr	₹108.00 Cr	₹108.00 Cr
Reserves & Surplus	₹640.00 Cr	₹774.00 Cr	₹1,225 Cr	₹1,377 Cr	₹1,452 Cr	₹1,663 Cr	₹2,490 Cr	₹3,244 Cr	₹3,930 Cr	₹4,003 Cr	₹4,365 Cr	₹5,192 Cr
Borrowings (Debt)	₹888.00 Cr	₹1,094 Cr	₹842.00 Cr	₹980.00 Cr	₹1,036 Cr	₹1,079 Cr	₹1,482 Cr	₹1,777 Cr	₹2,015 Cr	₹2,577 Cr	₹2,764 Cr	₹2,518 Cr
Total Liabilities	₹1,888 Cr	₹2,224 Cr	₹2,653 Cr	₹3,017 Cr	₹3,331 Cr	₹3,750 Cr	₹5,751 Cr	₹6,968 Cr	₹7,660 Cr	₹8,387 Cr	₹9,336 Cr	₹10,511 Cr
Fixed Assets	₹801.00 Cr	₹1,021 Cr	₹1,230 Cr	₹1,481 Cr	₹1,629 Cr	₹1,726 Cr	₹2,171 Cr	₹2,652 Cr	₹3,409 Cr	₹3,890 Cr	₹4,123 Cr	₹4,371 Cr
Total Assets	₹1,888 Cr	₹2,224 Cr	₹2,653 Cr	₹3,017 Cr	₹3,331 Cr	₹3,750 Cr	₹5,751 Cr	₹6,968 Cr	₹7,660 Cr	₹8,387 Cr	₹9,336 Cr	₹10,511 Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operations (CFO)	-₹65.00 Cr	₹182.00 Cr	₹332.00 Cr	₹342.00 Cr	₹298.00 Cr	₹347.00 Cr	₹733.00 Cr	₹911.00 Cr	₹994.00 Cr	₹666.00 Cr	₹602.00 Cr	₹1,624 Cr
Cash from Investing (CFI)	-₹397.00 Cr	-₹312.00 Cr	-₹289.00 Cr	-₹384.00 Cr	-₹253.00 Cr	-₹221.00 Cr	-₹941.00 Cr	-₹914.00 Cr	-₹997.00 Cr	-₹822.00 Cr	-₹680.00 Cr	-₹1,086 Cr
Cash from Financing (CFF)	₹486.00 Cr	₹103.00 Cr	-₹54.00 Cr	₹42.00 Cr	-₹45.00 Cr	-₹128.00 Cr	₹255.00 Cr	₹30.00 Cr	-₹27.00 Cr	₹250.00 Cr	₹39.00 Cr	-₹525.00 Cr
Free Cash Flow (FCF)	-₹447.00 Cr	-₹144.00 Cr	₹55.00 Cr	-₹49.00 Cr	₹44.00 Cr	₹125.00 Cr	₹49.00 Cr	₹34.00 Cr	₹6.00 Cr	-₹10.00 Cr	₹61.00 Cr	₹560.00 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days (DSO)	78	91	109	101	113	102	99	100	96	120	132	115
Inventory Days	210	176	186	201	201	234	266	293	222	277	285	317
Cash Conversion Cycle (Days)	186	178	199	195	170	177	166	247	224	240	276	263
ROCE %	14%	16%	16%	14%	8%	14%	40%	26%	23%	7%	9%	18%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹309.27 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹2,429.00

DCF Fair Value

₹309.27

Graham Number

₹211.52

Margin of Safety

-89.1%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹309.27

Premium / Overvalued (Margin: -89.1%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹301	₹298	₹296	₹293
10%	₹307	₹304	₹301	₹298
12%	₹312	₹309	₹306	₹304
14%	₹318	₹315	₹312	₹309

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹309	Fairly Valued
Benjamin Graham Number	₹212	Market Priced
Historical Sector P/E	₹446	Premium
EV / EBITDA Multiplier	₹2,550	In-Line
Free Cash Flow Yield Model	₹2,380	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 9/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

9 / 9 Pass

Altman Z-Score

4.36 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Debt/Equity: 0.48x (Safe)

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 28.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

27.47%

FIIs (Foreign)

28.00%

DIIs (Domestic)

13.73%

Government

0.15%

Public / Retail

30.79%

Swipe → to view historical quarters

Category	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
+ Promoters	27.20%	27.18%	27.18%	27.18%	27.18%	27.62%	27.62%	27.60%	27.60%	27.49%	27.49%	27.47%
+ FIIs (Foreign Portfolio)	24.03%	25.39%	25.98%	25.67%	26.08%	25.56%	25.51%	25.70%	26.17%	26.52%	25.82%	28.00%
+ DIIs (Mutual Funds / Insurance)	11.01%	11.13%	11.78%	13.56%	13.05%	12.74%	11.78%	11.94%	11.72%	12.42%	13.96%	13.73%
+ Public (Retail & HNIs)	37.75%	36.30%	35.07%	33.59%	33.69%	34.09%	35.09%	34.78%	34.52%	33.57%	32.73%	30.79%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

LAURUSLABS Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

LAURUSLABS Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

LAURUSLABS Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹3,109.12

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹2,720.48

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 100x P/E.

🐻 Bear Case (15%) -12.0%

₹2,137.52

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 20:57 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ LAURUS LABS Ltd (LAURUSLABS)	Target Stock	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Torrent Pharmaceuticals Ltd (TORNTPHARM)	Sector Peer	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr
Dr Reddys Laboratories Ltd (DRREDDY)	Active Ingredients & Biosimilars	₹1,377.00	-0.58%	30.6x	11.2%	13.0%	0.20	₹98,492 Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	20:57:35 IST	✓ Live Sync
Financial Statements (10Y)	LAURUS LABS Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

LAURUS LABS Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About LAURUS LABS Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title